Panelists:

Dave Lahr, PhD

Senior Director of Bioinformatics
Foghorn Therapeutics

View Bio

Panelist

Dave Lahr, PhD

Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days of the company, Lahr also setup and led research informatics, IT and information security. Prior to Foghorn, Lahr worked as a computational biologist and software engineer at the Broad Institute (first for the Center of Development of Therapeutics, and then at the Connectivity Map and PRISM groups within the Cancer Program).

Close

As drug developers turn toward more targeted and mechanism-based approaches, understanding how therapeutics alter transcriptional activity is essential. For potential candidates that act on the epigenome or chromatin-associated proteins, traditional gene expression assays are not sufficient to fully uncover the mechanism of action (MOA) or predict patient response.

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to drug treatment. During the webinar, you will learn how assays such as CUT&RUN (e.g. EpiCypher’s CUTANA™ CUT&RUN), ATAC-seq, and bisulfite sequencing map chromatin dynamics at high resolution, offering a more precise readout of MOA. He will share data from case studies of targeted protein degraders and enzyme inhibitors that demonstrate how epigenomic tools support MOA characterization and accelerate drug development.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

Produced with support from: